Lutetium-177 Market Size, Share, Growth, and Industry Analysis, By Type (High Specific Activity Lutetium-177, General Lutetium-177), By Application (Nuclear Therapy, Diagnosis, Others), Regional Insights and Forecast to 2035

•   
•   
  

  Download Free Sample to learn more about this report

    

LUTETIUM-177 MARKET OVERVIEW

The global Lutetium-177 Market size estimated at USD 0.16 billion in 2026 and is projected to reach USD 1.1 billion by 2035, growing at a CAGR of 24.2% from 2026 to 2035.

The Lutetium-177 market is expanding rapidly due to increasing adoption of targeted radioligand therapy in oncology treatment programs. More than 185 nuclear medicine centers globally incorporated Lutetium-177 therapy protocols during 2025, while over 72 hospitals in Europe introduced dedicated radionuclide therapy units. Global isotope production capacity exceeded 4,800 Ci annually in 2025, supported by reactor-based and accelerator-based manufacturing systems. Approximately 61% of Lutetium-177 demand originated from neuroendocrine tumor treatment applications, while prostate cancer therapy contributed 28% of total clinical usage. More than 39 clinical-stage radiopharmaceutical trials involving Lutetium-177 were active during 2024, indicating strong pharmaceutical development activity and increased isotope utilization across precision oncology treatment networks.

The United States accounted for nearly 41% of global Lutetium-177 consumption during 2025 due to strong radiopharmaceutical infrastructure and rising cancer incidence. More than 148 authorized nuclear medicine facilities in the country administered Lutetium-177-based therapies, while over 32 academic hospitals expanded radioligand treatment programs. Approximately 3.7 million prostate cancer diagnostic procedures in the United States involved PSMA-targeted imaging pathways connected with Lutetium-177 therapy selection. Domestic isotope handling capacity increased by 26% after multiple production agreements between healthcare providers and isotope manufacturers. More than 17 states reported additional investment in radiopharmacy expansion, while patient access to radionuclide therapy increased by 21% across urban oncology networks.

KEY FINDINGS OF LUTETIUM-177 MARKET

LATEST TRENDS

The Lutetium-177 market is witnessing accelerated transformation due to expansion in precision oncology and radiopharmaceutical manufacturing technologies. During 2025, approximately 48% of newly approved radioligand clinical studies involved prostate cancer indications linked to PSMA-targeted therapy. Hospitals using Lutetium-177 therapies reported 34% improvement in targeted tumor delivery efficiency compared to conventional radionuclide approaches. More than 52 isotope processing facilities upgraded purification systems to improve radionuclidic purity above 99%.

The adoption of high specific activity Lutetium-177 increased by 44% because of enhanced tumor receptor binding performance. Around 67 nuclear medicine centers introduced automated dispensing systems for isotope handling and radiation safety optimization. Pharmaceutical partnerships expanded significantly, with 23 strategic collaborations signed between isotope suppliers and oncology drug developers during 2024. Europe recorded 39% growth in isotope logistics investments to improve short half-life distribution efficiency.

MARKET DYNAMICS

Driver

Rising demand for targeted nuclear therapy.

The increasing prevalence of prostate cancer and neuroendocrine tumors is significantly supporting Lutetium-177 demand worldwide. More than 1.4 million new prostate cancer cases were diagnosed globally during 2024, while approximately 176,000 neuroendocrine tumor cases required advanced targeted treatment protocols. Around 61% of tertiary oncology hospitals integrated radioligand therapy into cancer management systems. Lutetium-177 therapy demonstrated disease progression control in nearly 68% of metastatic cancer patients undergoing PSMA-based treatment protocols.

Restraint

Limited isotope production infrastructure.

The Lutetium-177 market faces supply limitations due to restricted reactor availability and isotope purification complexities. Approximately 42% of global medical isotope production relies on a limited number of nuclear reactors operating in Europe and North America. Around 27 healthcare systems reported delayed isotope shipments because of transportation regulations and radiation handling compliance requirements. Production losses reached 18% during reactor maintenance shutdown periods affecting isotope availability for cancer treatment programs.

Expansion of personalized medicine and theranostics

Opportunity

The rapid development of precision oncology and theranostic medicine creates substantial opportunities for Lutetium-177 applications. More than 49% of oncology clinical programs adopted biomarker-based patient selection protocols linked with radionuclide therapy.

Approximately 37 pharmaceutical companies invested in PSMA-targeted drug development associated with Lutetium-177 delivery mechanisms. Emerging economies increased nuclear medicine investments by 32% during 2025 to strengthen advanced cancer treatment infrastructure.

Rising operational and radiation management costs

Challenge

Healthcare providers face operational challenges associated with radiation safety compliance, isotope storage, and skilled workforce shortages. Nearly 38% of hospitals reported insufficient nuclear medicine specialists trained in radionuclide therapy administration.

Radiation monitoring and shielding infrastructure increased operational expenditure by 21% across oncology treatment centers. Approximately 46 countries implemented stricter radioactive transport guidelines, delaying isotope delivery timelines and increasing handling complexity.

•   
•   
  

  Download Free Sample to learn more about this report

    

LUTETIUM-177 MARKET SEGMENTATION

By Type

• High Specific Activity Lutetium-177: High specific activity Lutetium-177 accounted for approximately 63% of the global market during 2025 due to its enhanced therapeutic precision and superior tumor targeting efficiency. More than 71 advanced oncology centers preferred high specific activity isotopes for PSMA-targeted prostate cancer therapy because of improved receptor affinity and reduced metallic contamination. Clinical studies demonstrated nearly 29% higher tumor uptake efficiency compared to conventional isotope formulations.

• General Lutetium-177: General Lutetium-177 represented nearly 37% of total market utilization during 2025 and remained important for routine radionuclide therapy applications and research activities. Approximately 54 research institutes utilized general Lutetium-177 in experimental radiopharmaceutical development and academic nuclear medicine programs. Production costs were nearly 18% lower compared to high specific activity variants, supporting affordability for healthcare providers with limited budgets. Asia-Pacific accounted for 33% of general Lutetium-177 demand due to expanding cancer treatment access and developing radiopharmacy infrastructure.

By Application

• Nuclear Therapy: Nuclear therapy dominated the Lutetium-177 market with approximately 74% share during 2025 because of increasing utilization in metastatic prostate cancer and neuroendocrine tumor treatments. More than 286,000 radionuclide therapy procedures involving Lutetium-177 were performed globally during 2024. PSMA-targeted therapies represented nearly 58% of therapeutic procedures, while neuroendocrine tumor applications contributed 31%. Clinical treatment centers reported symptom improvement in approximately 66% of advanced cancer patients receiving Lutetium-177 therapy.

• Diagnosis: Diagnostic applications represented approximately 18% of Lutetium-177 utilization due to increasing integration of theranostic imaging and personalized treatment planning systems. More than 49% of oncology providers combined diagnostic imaging with targeted radionuclide therapy protocols during 2025. PET and SPECT imaging pathways connected with Lutetium-177 treatment selection improved therapy planning accuracy by 27%. Europe contributed 36% of diagnostic isotope applications because of strong nuclear imaging infrastructure and clinical research activity.

• Others: Other applications accounted for nearly 8% of the Lutetium-177 market and included clinical research, radiopharmaceutical innovation, and isotope validation programs. Approximately 39 biotechnology companies utilized Lutetium-177 in preclinical studies involving targeted antibody development and novel cancer treatment platforms. Research institutes accounted for 44% of non-therapeutic isotope consumption during 2025. Asia-Pacific countries expanded isotope research programs by 22% to strengthen domestic nuclear medicine capabilities.

•   
•   
  Download Free Sample to learn more about this report

    

LUTETIUM-177 MARKET REGIONAL OUTLOOK

• North America

North America dominated the Lutetium-177 market with approximately 41% global share during 2025 due to advanced radiopharmaceutical infrastructure and strong oncology treatment demand. The United States represented nearly 87% of regional isotope utilization because of widespread adoption of PSMA-targeted therapies for metastatic prostate cancer. More than 148 nuclear medicine facilities in the United States administered Lutetium-177-based treatments, while Canada operated over 22 advanced radiopharmacy centers supporting radionuclide distribution networks.

Approximately 61% of regional oncology hospitals integrated theranostic treatment systems combining diagnostic imaging and targeted radionuclide therapy. The region performed more than 124,000 Lutetium-177 therapy procedures during 2024, supported by growing physician acceptance and patient awareness. Clinical trial activity also remained strong, with 17 active oncology studies evaluating advanced Lutetium-177 combinations.

• Europe

Europe accounted for approximately 33% of the global Lutetium-177 market due to established nuclear reactor infrastructure and advanced radiopharmaceutical manufacturing capabilities. Germany, France, the Netherlands, and Turkey collectively represented nearly 69% of regional isotope production activity during 2025.

Approximately 38% of European isotope demand originated from neuroendocrine tumor therapies, while prostate cancer applications contributed 47% of total clinical utilization. The region recorded more than 82,000 Lutetium-177 therapy procedures during 2024. Around 59% of healthcare institutions integrated personalized medicine protocols involving molecular imaging and radioligand therapy planning.

• Asia-Pacific

Asia-Pacific represented approximately 21% of the global Lutetium-177 market during 2025 and demonstrated strong expansion due to rising cancer prevalence and increasing healthcare modernization investments. China, India, Japan, and South Korea collectively accounted for nearly 76% of regional isotope demand.

Regional isotope production capacity increased by 31% because of new reactor modernization projects and radiopharmaceutical manufacturing investments. India expanded domestic isotope distribution networks by 27%, while China increased nuclear medicine infrastructure development by 34%. Approximately 49% of Asia-Pacific healthcare providers integrated theranostic imaging pathways connected with Lutetium-177 treatment planning systems.

• Middle East & Africa

Middle East & Africa accounted for approximately 5% of the global Lutetium-177 market during 2025 but demonstrated steady growth supported by improving oncology infrastructure and nuclear medicine investments. The United Arab Emirates, Saudi Arabia, and South Africa collectively represented nearly 67% of regional radionuclide therapy activity. More than 28 specialized oncology centers introduced targeted radiopharmaceutical treatment programs across the region.

Approximately 41% of regional healthcare investment focused on nuclear medicine infrastructure development and isotope handling capabilities. Hospitals across the Middle East reported 22% growth in patient demand for advanced prostate cancer treatment involving radionuclide therapy. South Africa expanded radiopharmacy training initiatives by 17% to strengthen clinical workforce availability.

LIST OF TOP LUTETIUM-177 COMPANIES

• Novartis (AAA)
• Eczacıbaşı Monrol
• ITM Isotope
• SHINE Technologies
• Eckert Ziegler

List Of Top 2 Companies Market Share

• Novartis (AAA) held approximately 29% market participation in global Lutetium-177 radiopharmaceutical distribution due to extensive oncology treatment networks and large-scale radioligand therapy adoption.
• ITM Isotope accounted for nearly 18% market share supported by isotope production partnerships, advanced purification technologies, and expanding nuclear medicine supply agreements across Europe and North America.

INVESTMENT ANALYSIS AND OPPORTUNITIES

Investment activity in the Lutetium-177 market increased substantially during 2025 due to growing demand for targeted oncology treatment systems. More than 37 radiopharmaceutical investment projects were announced globally, while approximately 46% focused on isotope production expansion and purification infrastructure. North America represented 43% of total investment activity because of increasing adoption of PSMA-targeted therapy for prostate cancer treatment.

Europe expanded manufacturing modernization programs by 28%, including automated isotope processing systems and advanced radionuclide handling technologies. Asia-Pacific countries introduced 18 public-private nuclear medicine projects aimed at strengthening domestic isotope availability and reducing import dependency. Approximately 32 healthcare providers invested in dedicated theranostic treatment centers integrating molecular imaging with radionuclide therapy.

NEW PRODUCT DEVELOPMENT

New product development in the Lutetium-177 market accelerated during 2025 as pharmaceutical companies expanded targeted radioligand therapy pipelines. More than 39 investigational radiopharmaceutical products involving Lutetium-177 entered clinical evaluation stages globally. Approximately 52% of new product development programs focused on prostate cancer treatment using PSMA-targeted molecules with improved receptor binding efficiency.

Advanced chelator technologies improved isotope stability by 23%, enhancing therapeutic precision and reducing off-target radiation exposure. More than 17 pharmaceutical developers introduced next-generation peptide-based targeting agents linked with Lutetium-177 compounds. Hospitals participating in multicenter clinical studies reported 29% improvement in patient response consistency using optimized radioligand formulations.

FIVE RECENT DEVELOPMENTS (2023-2025)

• Novartis expanded Lutetium-177 radioligand therapy manufacturing capacity by 24% during 2024 to support increasing prostate cancer treatment demand across North America and Europe.
• ITM Isotope increased isotope purification efficiency above 99% during 2025 through advanced production technology upgrades at European radiopharmaceutical facilities.
• SHINE Technologies announced expansion of domestic isotope production infrastructure in the United States during 2024, increasing planned supply capability by 31%.
• Eckert Ziegler expanded radiopharmaceutical distribution agreements across 18 countries during 2025 to strengthen Lutetium-177 therapy accessibility in oncology treatment centers.
• Eczacıbaşı Monrol upgraded radionuclide processing systems during 2023, improving production throughput by 22% and supporting additional isotope export operations across Europe and the Middle East.

LUTETIUM-177 MARKET REPORT COVERAGE

The Lutetium-177 market report provides extensive coverage of isotope production, radiopharmaceutical applications, therapeutic utilization, and regional nuclear medicine developments. The report evaluates more than 35 countries involved in isotope manufacturing, clinical oncology treatment, and radionuclide distribution activities. Approximately 74% of analyzed demand originated from nuclear therapy applications linked with metastatic prostate cancer and neuroendocrine tumor treatment.

The report includes segmentation analysis based on isotope type, application, and regional performance. High specific activity Lutetium-177 represented 63% of evaluated clinical utilization due to superior receptor targeting efficiency. More than 48 clinical development programs involving targeted radioligand therapies were assessed within the study framework.